Is trastuzumab every three weeks ready for prime time?

被引：8

作者：

Cobleigh, M ^{[1
]}

Frame, D ^{[1
]}

机构：

[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 21期

关键词：

D O I：

10.1200/JCO.2003.07.984

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3900 / 3901

页数：2

共 10 条

[1] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[2]

CASTELLON XC, 2002, P AN M AM SOC CLIN, V20, pA19

[3] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[4]

GELMON K, 2001, P AN M AM SOC CLIN, V20, pA69

[5]

HARRIS K, 2002, P AN M AM SOC CLIN, V21, pA123

[6] Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel [J].

Leyland-Jones, B ;

Gelmon, K ;

Ayoub, JP ;

Arnold, A ;

Verma, S ;

Dias, R ;

Ghahramani, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3965-3971

[7] Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment [J].

Pegram, MD ;

Lipton, A ;

Hayes, DF ;

Weber, BL ;

Baselga, JM ;

Tripathy, D ;

Baly, D ;

Baughman, SA ;

Twaddell, T ;

Glaspy, JA ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2659-2671

[8] Cardiac dysfunction in the trastuzumab clinical trials experience [J].

Seidman, A ;

Hudis, C ;

Pierri, MK ;

Shak, S ;

Paton, V ;

Ashby, M ;

Murphy, M ;

Stewart, SJ ;

Keefe, D .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1215-1221

[9] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[10] Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer [J].

Vogel, CL ;

Cobleigh, MA ;

Tripathy, D ;

Gutheil, JC ;

Harris, LN ;

Fehrenbacher, L ;

Slamon, DJ ;

Murphy, M ;

Novotny, WF ;

Burchmore, M ;

Shak, S ;

Stewart, SJ ;

Press, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :719-726

← 1 →